Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD10367 in Psoriasis
NCT03025282Phase 2Completed
- Sponsor
- Galderma
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CD10367 in Psoriasis vulgaris (PV), sponsored by Galderma. Started Nov 2016; status: completed.
02
Drugs
CD10367
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT03025282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025282.